The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of napsin A-specific T cell clonotypes with durable clinical benefit to immunotherapy in patients with metastatic NSCLC.
 
Natalie J. Miller
No Relationships to Disclose
 
Christina S Baik
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/UCB Japan; Genentech/Roche; Janssen; Pfizer
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Rain Therapeutics (Inst); Spectrum Pharmaceuticals (Inst); TP Therapeutics (Inst)
 
Joel W. Neal
Honoraria - Biomedical Learning Institute; Clinical Care Options; CME Matters; HMP Education; Medical Educator Consortium; Medscape; MJH Life Sciences; Peerview; Prime Oncology; Projects in Knowledge; Research to Practice; Rockpointe CME
Consulting or Advisory Role - Abbvie; Amgen; Anheart Therapeutics; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; D2G Oncology; Exelixis; Genentech/Roche; Gilead Sciences; Iovance Biotherapeutics; Janssen Oncology; Lilly; Mirati Therapeutics; Natera; Novartis; Novocure; Regeneron; Sanofi/Regeneron; Summit Therapeutics; Surface Oncology; Takeda; Turning Point Therapeutics
Research Funding - AbbVie (Inst); Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties
 
A. McGarry Houghton
Research Funding - JJ Innovative Medicine
 
Viswam S. Nair
Stock and Other Ownership Interests - Moderna Therapeutics; Pfizer
Consulting or Advisory Role - Eurofins Viracor, Inc; Freenome; Verathon Inc
Research Funding - Biodesix; Roche
 
Rafael Santana-Davila
Consulting or Advisory Role - Amgen; AstraZeneca; Catalyst Pharmaceuticals; Genentech/Roche; Genentech/Roche; Mirati Therapeutics
Research Funding - Abbvie (Inst); Alpine Immune Sciences (Inst); ALX Oncology (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeyondSpring Pharmaceuticals (Inst); Daiichi Sankyo/Lilly (Inst); Genentech (Inst); ISA Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst); Pfizer (Inst)
 
Sylvia Lee
Research Funding - Bristol-Meyers Squibb (Inst); Iovance Biotherapeutics (Inst); Kite, a Gilead company (Inst); PACT Pharma (Inst); SeaGen (Inst); Tmunity Therapeutics, Inc. (Inst)
 
Keith D. Eaton
Research Funding - Mirati Therapeutics (Inst)
 
Renato G. Martins
Honoraria - Sanofi; Takeda
Research Funding - Eisai (Inst); Genentech (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Other Relationship - Takeda; Takeda; Takeda
 
Heather A. Wakelee
Consulting or Advisory Role - Mirati Therapeutics
Research Funding - ACEA Biosciences (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); Merck (Inst); Novartis (Inst); Seagen (Inst); Xcovery (Inst)
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Merck
 
Sukhmani Kaur Padda
Honoraria - CME Solutions; Curio Science; Janssen; Jazz Pharmaceuticals; MECC Global Meetings; Medical Oncology Association of Southern California; Medical Oncology Association of Southern California; Nanobiotix; OncLive/MJH Life Sciences; Physicans' Education Resource; The New England Journal of Medicine
Consulting or Advisory Role - Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Blueprint Medicines; G1 Therapeutics; Genentech; Genzyme; Janssen Oncology; Janssen Oncology; Jazz Pharmaceuticals; Mirati Therapeutics; Mirati Therapeutics; RayzeBio; Regeneron; Sanofi
Research Funding - BioAtla (Inst); Takeda (Inst)
Other Relationship - NIH/NCI; OncLive/MJH Life Sciences
 
Shin-Heng Chiou
No Relationships to Disclose
 
Diane Tseng
Research Funding - Gilead Sciences
Patents, Royalties, Other Intellectual Property - Use of Anti-CD47 Agents to Enhance Immunization, U.S. Patent Application No 16/048,862